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BACKGROUND:Disease-specific instruments, commonly incorporated into clinical
trials, provide comprehensive insights into the quality-of-life of patients experi-
encing that disease. However it is not possible to directly elicit preference-based
valuations from such instruments for use in cost-utility analysis. OBJECTIVES: To
provide a mapping algorithm for estimating EQ-5D index scores from the Urinary
Incontinence-specific Quality of Life Questionnaire (I-QOL) based on nationally
representative samples of patients with idiopathic or neurogenic overactive blad-
der (OAB) syndrome using EQ-5D preference valuations based on both the UK and
US general populations. METHODS: Analyses were conducted for 2505 patients
from the Adelphi OAB Disease Specific Programme, a cross-sectional study of pa-
tients consulting with idiopathic or neurogenic OAB, undertaken in the USA and
Europe in 2010. A range of statistical mapping techniques including OLS, CLAD,
Tobit, GLMs, reverse GLMs and reverse two-part GLMs were used. Ten-fold cross
validation techniques were employed to calculate Mean Absolute Error (MAE) and
Root Mean Squared Error (RMSE) goodness of fit statistics. Various predictor lists
together with a method combining stepwise selection with multivariable fractional
polynomial techniques to allow non-linear relationships to feature were pursued.
RESULTS: Choice of predictors was consistent for both the UK and USA EQ-5D
tariffs. For idiopathic, the best model included IQOL Composite Score and age (both
modelled non-linearly). For neurogenic the best model was I-QOL Social Embar-
rassment Score modelled linearly only. Best fit results were better in the idiopathic
(n2351: MAE  0.10. RMSE  0.14) than neurogenic sample (n254: MAE  0.17.
RMSE  0.22). CONCLUSIONS: This research provides algorithms for mapping
EQ-5D index scores from I-QOL allowing calculation of appropriate preference-
based health-related quality-of-life scores for use in cost-effectiveness analyses
when only I-QOL data are available. The strongest results were for idiopathic
patients, but those for neurogenic are consistent with other published mapping
studies.
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OBJECTIVES: To construct and validate a prediction model of preference-adjusted
health status (EQ-5D) for metastatic castrate resistant prostate cancer (CRPC) pa-
tients using FACT-P (Functional Assessment of Cancer Therapy–Prostate), a multi-
dimensional prostate cancer-specific health-related quality of life instrument.
METHODS: Patient-level data were obtained for CRPC patients from the Adelphi
Group Prostate Cancer Disease Specific Program (DSP) data, a multinational cross-
sectional study of prostate cancer patients conducted in France, Germany, Italy,
Spain and UK during 2009 to 2010. EQ-5D and FACT-P were available for a subset of
patients. Country specific utility values were derived from EQ-5D profiles based on
value sets available for 8 countries and the EU. Predictive validity of the FACT-P
subscales and patient demographics for utility was tested using ordinary least
square (OLS), median, Gamma and Tobit multivariate regression models, and pre-
dictive algorithms developed to convert FACT-P to EQ-5D utilities for different
value sets. RESULTS: Values for both FACT-P (mean85.4) and EQ-5D were avail-
able for 291 patients (mean age70.7). A total of 57% of patients were treated with
chemotherapy at the time of assessment, 10% had prior chemotherapy, and 33%
were chemotherapy naive. Mean estimated country-specific utilities varied be-
tween 0.59 (New Zealand) and 0.76 (Germany). OLS and TOBIT regression were the
best-performing models, explaining between 34.6% (Danish) and 46.8% (EU) of the
observed EQ-5D variation. The physical and functional well-being subscales had
the highest explanatory value. The social well-being and prostate cancer specific
subscales, and patient age and BMI did not have statistically significant additional
explanatory value. CONCLUSIONS: The developed algorithms enable to translate
cancer-specific health-related quality of life measures to preference-adjusted
health status in metastatic CRPC patients, taking into account local country-spe-
cific utility weights. The findings will help to develop health status adjustments in
cost-utility analyses used in appraising health care technologies.
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OBJECTIVES: To carry out cost utility analysis, utility values can be derived using
generic preference based measures such as EQ-5D or SF-6D. In some settings ge-
neric measures are not used, and mapping functions are being developed to predict
utility scores from condition specific measures. The aim of this study is to map the
DHP-18 - a diabetes-specific HRQoL patient reported outcome measure - onto
EQ-5D and SF-6D utility scores for type 1 and type 2 diabetes mellitus populations.
METHODS: The data used was pooled from a longitudinal study of quality of life in
diabetes. OLS, GLS and Tobit models regressing DHP dimensions and, separately,
DHP items onto EQ-5D and SF-6D index scores for both type 1 (n236) and type 2
(n2358) diabetes populations were applied. RESULTS: For both the EQ-5D and
SF-6D, the GLS model mapping selected DHP-18 item scores, squared item scores,
age and gender onto the utility index provided the best fit, and this was the case for
both the type 1 and type 2 populations (R2 EQ-5D type 1: 0.516; EQ-5D type 2: 0.290;
SF-6D type 1: 0.647; SF-6D type 2: 0.396). The models under predict utility when the
state is severe and over predict when the state is mild. The error associated with
the models was lower for SF-6D than for EQ-5D due to differences in the range of
the measures. CONCLUSIONS: The DHP-18 items can predict both the EQ-5D and
SF-6D utility scores with acceptable precision with the mapping algorithm for the
SF-6D displaying a higher level of precision. The mapping functions developed
from the models can be used to predict utility scores in settings where the EQ-5D
or SF-6D have not been used alongside the DHP-18. However mapping should be
considered second best in comparison to using generic measures in research
studies.
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OBJECTIVES: We have previously developed an adjusted, limited dependent vari-
able, mixture model (ALDMM) approach for estimating EQ-5D utility values from a
range of covariates which reflects the upper bound, skewness and gaps in the
distribution of EQ-5D. The three class ALDMM has been demonstrated to perform
better than standard approaches on aggregate in a rheumatoid arthritis (RA) data-
set but was not superior at very poor health states. Here we refine the method and
apply it to a much larger RA dataset. METHODS: Using an observational dataset of
RA patients (n16,000) we estimate EQ-5D utility values (UK tariff) as a function of
Health Assessment Questionnaire (HAQ), pain, age and sex. This was done using
linear, Tobit, three and four class ALDMMs. We further adjusted the ALDMM to
account for the lower EQ-5D bound. RESULTS: EQ-5D is estimated as a function of
HAQ, pain and pain2 as well as age and sex. Previous results were replicated at
extremely poor health states in this very large dataset. By including the additional
adjustment for very poor health states, the ALDMM outperforms all others tested in
terms of model fit and appropriateness of the predictions across the entire range of
EQ-5D CONCLUSIONS: The ALDMM approach is designed to appropriately reflect
the range of challenges that arise from the EQ-5D distribution. Standard models are
not as appropriate and fit the data less well. It may be that an additional adjust-
ment to the ALDMM is required to model extremely serious health states, which
are often of critical importance in cost effectiveness models, though the relative
scarcity and credibility of data at this extreme remain a concern.
PODIUM SESSION III:
LOOKING BEYOND EXISTING HORIZONS
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OBJECTIVES: Treatments that impact upon survival form a high proportion of the
interventions appraised by the National Institute for Health and Clinical Excellence
(NICE). Survival data are commonly censored and therefore extrapolation is re-
quired to estimate the full impact of the new intervention. There are a range of
approaches for conducting survival analysis in these circumstances, and these can
lead to widely varying survival estimates and incremental cost-effectiveness ratios
(ICERs). We reviewed a subset of NICE Technology Appraisals (TAs) to identify and
analyse methods that are commonly used in practice. METHODS: We identified all
completed NICE TAs that appraised new treatments for advanced and/or meta-
static cancer and analysed methods for estimating survival and justifications for
the chosen approach.RESULTS: By December 2009 NICE had completed 45 TAs that
focussed on advanced and/or metastatic cancer. Parametric models were used in
71% of these. Weibull and exponential models were most commonly used (in 51%
and 44% of the reviewed TAs, respectively), with Gompertz, log-logistic, log normal
and gamma models used infrequently. Piecewise parametric models and other
more flexible methods were seldom used. Justifications of chosen approaches were
not systematic and were usually overly simplistic. CONCLUSIONS: Survival anal-
ysis methods differ significantly across NICE TAs. This is expected because differ-
ent methods are appropriate in different circumstances. However, the majority of
TAs did not take a systematic approach to survival analysis and did not fully justify
chosen methods. Therefore inappropriate methods may have been used. Different
models can lead to large variations in ICERs – for example in NICE TA178 log-logistic
models led to an ICER of £40,000, compared to £75,000 when Gompertz models were
used. Hence it is clearly of great importance to select appropriate models. This
review has contributed to a NICE Technical Support Document on extrapolation
with patient-level data.
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OBJECTIVES: Immunotherapies such as ipilimumab and IL-2 show delayed but
durable response leading to stabilization of symptoms and extended OS after an
initial drop-off in the KM curve. Our objective was to review and challenge cur-
rently available economic modelling methods when applied to such emerging ther-
apies with new mechanisms of action (MoA). METHODS: As alternatives to stan-
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dard OS extrapolation methods which fit ‘traditional’ parametric survival
distributions to patient-level data, two different methods were explored in the
modelling of OS beyond the trial duration (55 months) for the novel immunother-
apy ipilimumab. In the first approach, the hazard rate from the Kaplan-Meier (KM)
curve between 24 and 36 months (before reaching a plateau) was used to extend the
curve. In the second approach, different parametric curves were fitted to the period
of 18 months onwards. Akaike’s Information Criterion (AIC) was used to determine
the best fit curve. RESULTS: When compared to standard OS extrapolation meth-
ods, both methods exhibited a better visual fit to the data. Both approaches allow
the hazard of the extrapolated tail to be based on a section of the KM curve that is
more appropriate in describing the long-term survival of these patients. The haz-
ard rate approach does not allow for a formal comparison with AIC, but allows
extrapolation in line with the clinical interpretation. The ‘parametric curves’ ap-
proach allows for a statistically better fit with the patient level data using conven-
tional AIC criteria. Both methods are in line with long-term observations of immu-
notherapy.CONCLUSION: For novel cancer therapies whose KM curves are not well
described by standard survival distributions, other methods of extrapolation
should be explored in conjunction with an understanding of the clinical rationale.
In this case study, two alternatives are presented that describe the OS of immuno-
therapy patients in a more suitable way.
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OBJECTIVES: Conventional economic evaluation involves piecewise comparisons
of competing interventions at a single point in a broader care pathway.METHODS:
This approach is subject to several problems: a) there remains an ongoing debate
surrounding the appropriateness of threshold-based decision rules and whether
their repeated use will maximise health; b) restricting the model scope to a single
decision point means that other adoption decisions elsewhere in the disease path-
way may be treated as independent of the problem under consideration; and c) the
absence of model development guidance leads to inconsistencies between analy-
ses addressing similar decision problems. In light of these problems, this study
puts forward the notion of “Whole Disease Modelling.” This involves simulating
whole disease and treatment pathways within a single model, from preclinical
disease through to diagnosis and referral, adjuvant treatment, follow-up, potential
recurrence, palliative treatment, end-of-life care and eventual death. A method-
ological framework has been developed based on three key principles: 1) the model
boundary and breadth should capture all relevant aspects of the disease and its
treatment; 2) the model should be developed such that the decision node is con-
ceptually transferable across the pathway; and 3) the costs and consequences of
service elements should be structurally related. RESULTS: Case study applications
in colorectal cancer services suggest that Whole Disease Modelling is feasible and
may provide a consistent platform for economic analysis at virtually any point in a
disease pathway using multiple economic decision rules. CONCLUSIONS: The
value of the approach may be realised when: multiple decision problems require
formal economic analysis at a single timepoint; services are subject to rapid inno-
vation and the model can be re-used; a substantial proportion of currently provided
service elements have not previously been subjected to economic analysis, and;
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OBJECTIVES: The aim of this study was to investigate whether broadening the
evaluative space in an economic evaluation would lead to other outcomes, and
hence policy recommendations. METHODS: Two discrete choice experiments
(DCE) were conducted in a population of patients who had been treated for varicose
vein disease (N390) either by foam sclerotherapy or surgical stripping. In the
Health DCE the treatments were described in terms of health outcomes attributes
only (based on the EQ5D dimensions). In the Extended DCE the treatments were
described in terms of the same health outcomes attributes and other aspects (Wait-
ing time, Probability of retreatment and Nature of treatment). The differences in
the levels were collected in a clinical trial and entered into the preference models
to calculate the differnce in utility between those treatments. The 	U in both
models was standardised on a [-1,1] scale. The incremental costs of foamsclero-
therapy versus surgical stripping, as observed in the clinical trial, amounted to
-€1123. RESULTS: All attributes were statistically significant, except for Waiting
time and Probability of retreatment. The relative importances and the ranks of the
health attributes differed between the models. The patients preferred surgical
treatment if only health outcomes were considered, while the patients preferred
dermatological treatment if also aspects beyond health outcomes were considered
in the choice: 	Uhealth-0.0109; 	Uextended0.3971. When incremental utility
was based on health outcomes only alone, the incremental cost-utility ratio was
€103,027. When incremental utility was based broader outcomes, the incremental
utility ratio indicated dominance. CONCLUSIONS: The results suggest that recom-
mendation for policy would changed if not only health outcomes but also broader
outcomes are considered. The results confirm that a restriction to health outcomes
in the (economic) evaluation of health care leads to the maximization of health, but
not necessarily to the maximization of benefit in a broader sense.
PODIUM SESSION III:
FLOATING THRESHOLDS AND BY PASSES: RISK SHARING AND PATIENT
ACCESS
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OBJECTIVES: To identify existing knowledge about the costs and benefits, assessed
either quantitatively or qualitatively, of performance based reimbursement, risk
sharing schemes, patient access schemes, and flexible pricing schemes for
pharmaceuticals. METHODS: A systematic literature review was conducted using
PubMed for the period January 2008 - April 2011. The terms “risk sharing”, “flexible
pricing”, “patient access schemes”, and “performance-based reimbursement” were
searched in titles and abstracts.RESULTS:The search provided 62 records and after
screening the number was reduced to 31. After full assessments of these studies, a
total of 24 formed the basis of the review. More than 40 per cent of the publications
referred to the Multiple Sclerosis Risk Sharing Scheme implemented in the UK
since 2002. The review did not identify any cost benefit analysis evaluating the
overall economic impact of schemes in monetary terms. All studies discussed costs
and benefits qualitatively and in some cases, when known, some costs were re-
ported. Schemes’ key stakeholders – health service employees, companies, regu-
lators –bear different costs and benefits and conflicting incentives may arise. Costs
and benefits widely vary depending on the characteristics of the scheme.
CONCLUSIONS: There is lack of consensus on the welfare consequences of the
schemes and their social desirability. Identified benefits are countered by signifi-
cant costs and the overall balance remains unclear. Further research is necessary:
a) to assess in a transparent way to what extent the transactional costs and admin-
istrative burden are shared between payers and pharmaceutical companies, as
they constitute an important barrier for the implementation of the schemes, and b)
to aid design of a successful Value Based Pricing system for new medicines in the
UK, given the similar principles that underpin outcome-based schemes where
prices are set to match “real world” NHS value in practice.
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OBJECTIVES: It is widely recognised that the National Institute for Health and
Clinical Excellence (NICE) in the UK employs cost-effectiveness thresholds in
health technology appraisal decision-making. This incremental cost-effectiveness
ratio (ICER) threshold has been topic of much debate and is estimated to lie around
£30,000 per quality-adjusted life-year (QALY) gained. In December 2008, NICE ap-
proved supplementary advice to reconsider this threshold for life-extending, end-
of-life interventions. This policy applies to treatments indicated for small patient
populations with life expectancies of usually under 24 months, that typically pro-
long survival by at least 3 months. The aim of this study was to explore NICE’s
increased ICER threshold when end-of-life conditions are taken into account.
METHODS: All NICE technology appraisals issued between December 2008 and
June 2011 were reviewed. The appraisals in which end-of-life considerations ap-
plied were identified and ICERs from these appraisals were extracted. RESULTS: In
total, 53 single technology appraisals were published in the timeframe considered;
of these, only 13 fulfilled the end-of-life criteria, all concerning treatments for
cancer. The final ICERs of these 13 interventions ranged from £31,800 to £68,000,
although 10 out of 13 manufacturers employed patient access schemes to lower
these values. Both the highest ICER that was approved and the lowest ICER that was
not approved were £49,300 per QALY gained. Interestingly, both of these appraisals
concerned interventions for the treatment of advanced renal cell carcinoma, im-
plying that other factors must have been taken into account by NICE to reach this
judgement. CONCLUSIONS: Cost-effectiveness seems to be the most important
criterion for NICE in their health technology appraisals. For end-of-life, life-extend-
ing treatments, the cost-effectiveness threshold appears to lie around £50,000 per
QALY. However, review of individual appraisals shows that other factors such as
uncertainty in the estimates and unmet need are also taken into account in NICE’s
decision-making.
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EVIDENCE, PROCESS OR CONTEXT? EXAMINING THE FACTORS THAT DRIVE
COVERAGE DECISIONS OF PHARMACEUTICALS BY HEALTH TECHNOLOGY
ASSESSMENT BODIES IN EUROPE
Cerri K, Fernández JL, Knapp M
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OBJECTIVES: In Europe, Health Technology Assessment (HTA) bodies produce cov-
erage decisions that guide public funding of pharmaceuticals. This analysis exam-
ines and weights those factors that drive HTA coverage decisions, focusing on the
National Institute for Health and Clinical Excellence (NICE) in England and Wales,
the Scottish Medicines Consortium (SMC), the Dutch College voor Zorgverzekerin-
gen (CVZ), and the French Haute Autorité de Sante (HAS). METHODS: A dataset of
approximately 1000 HTA coverage decisions by NICE, SMC, CVZ and HAS from the
period 2004-2009 was created, containing more than 30 clinical, economic, process
and socio-economic factors extracted from published HTA reports. A three-cate-
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